预约演示
更新于：2025-01-06
Nifedipine
硝苯地平
更新于：2025-01-06
概要
基本信息
简介硝苯地平是一种小分子药物，可作为电压依赖性钙通道 (VDCC) 的阻断剂，VDCC 参与心血管系统中钙离子的调节。 通过抑制这些通道，硝苯地平减少钙流入平滑肌细胞，导致血管扩张和血压下降。 该药主要用于治疗高血压，包括肾血管性和原发性高血压，以及心绞痛和其他心血管疾病。 硝苯地平最初由拜耳公司开发和销售，并于 1975 年获得首次批准。从那时起，它已成为一种广泛用于治疗高血压和相关疾病的药物，尽管它的使用与潜在的副作用有关，如低血压、 头晕和头痛。 因此，应谨慎使用并在医疗保健专业人员的监督下使用。 |
药物类型 小分子化药 |
别名 Nifedine、Nifedipine (JP17/USP/INN)、Nifedipine oral + [40] |
靶点 |
作用机制 Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors) |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 德国 (1975-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H18N2O6 |
InChIKeyHYIMSNHJOBLJNT-UHFFFAOYSA-N |
CAS号21829-25-4 |
关联
270
项与 硝苯地平 相关的临床试验NCT05551104
Safest Choice of Antihypertensive Regimen for Postpartum Hypertension: A Randomized Control Trial (SCARPH)
CTR20243800
预评估受试制剂硝苯地平控释片（规格：30 mg）与参比制剂拜新同®（规格：30 mg）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、三制剂、三周期、三序列、交叉生物等效性研究
NCT06220721
Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following
100 项与 硝苯地平 相关的临床结果
登录后查看更多信息
100 项与 硝苯地平 相关的转化医学
登录后查看更多信息
100 项与 硝苯地平 相关的专利（医药）
登录后查看更多信息
19,626
项与 硝苯地平 相关的文献（医药）2025-03-01DEVELOPMENTAL BIOLOGY
Automated non-invasive laser speckle imaging of the chick heart rate and extraembryonic blood vessels and their response to Nifedipine and Amlodipine drugs
Article
作者: Yang, Changhuei ; Bronner, Marianne E ; Dong, Zhenyu ; Sato, Yuki ; Mahler, Simon ; Readhead, Carol
Using our recently developed laser speckle contrast imaging (LSCI) to visualize blood vessels and monitor blood flow noninvasively, we test the utility of the developing chick heart as a functional model for drug screening. To this end, we examined the effects of antihypertensive agents Nifedipine and Amlodipine, belonging to the L-type calcium channel antagonist family, on blood flow visualized noninvasively through the intact shell. Guided by the live view mode, the drugs were injected through the shell and ventral to HH16-19 chick embryos. Our results show a significant reduction in the chick's heart rate, blood flow, and vascular size within 5-20 min after Nifedipine or Amlodipine injection. For moderate Nifedipine concentrations, these parameters returned to initial values within 2-3 h. Nifedipine showed a rapid reduction in heart rate and blood flow dynamics at a concentration ten times lower than Amlodipine. These findings show that our LSCI system can monitor and distinguish the chick heart's response to injected drugs from the same family. This serves as proof-of-concept, paving the way for a rapid, cost-effective, and quantitative test system for screening drugs that affect the cardiovascular system of live chick embryos. Live noninvasive imaging may also provide insights into the development and functioning of the vertebrate heart.
2025-01-02WOMEN & HEALTH
Magnesium sulfate versus nifedipine for tocolysis: meta-analysis of randomized controlled trials
Review
作者: de Medeiros, Kleyton Santos ; Vale, Adson José Martins ; Martins, Rand Randall ; de Souza, Amaxsell Thiago Barros ; de Lima Machado, Maria Letícia ; Sarmento, Ayane Cristine Alves ; Costa, Ana Paula Ferreira ; Cobucci, Ricardo Ney ; Costa, Tatiana Xavier da
Preterm labor, defined as contractions occurring every 5-10 minutes with cervical changes before the 37th week of estimated gestation, is a significant cause of perinatal mortality. This meta-analysis aims to evaluate the effectiveness and safety of magnesium sulfate compared to nifedipine in managing preterm labor. The systematic review protocol was registered with PROSPERO (CRD42023422419). Manuscripts published up to September 2024 were systematically searched in databases. Dichotomous data were pooled as odds ratios using a random-effects model with the Mantel-Haenszel method, while continuous data were analyzed as mean ± standard deviation values, mean differences, and standardized mean differences using inverse-variance fixed-effects analysis. Fifteen randomized clinical trials (RCTs) were included, enrolling a total of 2,186 pregnant women. Nifedipine showed a greater effect compared to a 4-gram IV dose of magnesium sulfate. However, the efficacy of these tocolytics in prolonging pregnancy by 48 hours did not significantly differ between nifedipine and a 6-gram IV dose of magnesium sulfate. Additionally, magnesium sulfate was associated with more adverse drug reactions. The moderate certainty of evidence found here requires confirmation in large, adequately powered RCTs.
2025-01-01American Journal of Obstetrics & Gynecology MFM
Amlodipine versus nifedipine ER for the management of postpartum hypertension: a noninferiority randomized controlled trial
Article
作者: Carlson, Laura ; Self, Stella ; Pratt, Katelyn ; Lordo, Ross
BACKGROUND:
Postpartum hypertension is an increasingly prevalent problem and optimizing its treatment is imperative in reducing maternal morbidity and improving long-term health outcomes. Despite this, data on treatment of postpartum hypertension is limited. While most available studies focus on labetalol and nifedipine ER, these medications are not frequently used for hypertension treatment in the non-obstetric setting. As we aim to establish best practices for managing postpartum hypertension, use of more commonly encountered antihypertensives should be evaluated.
OBJECTIVE:
To evaluate the use of amlodipine for the treatment of postpartum hypertension, as assessed by postpartum length of stay.
STUDY DESIGN:
In a pragmatic, randomized controlled noninferiority trial, patients were assigned to amlodipine or nifedipine ER for treatment of postpartum hypertension. The primary outcome was time from delivery until discharge with a noninferiority limit of 24 hours. A sample size of 132 was needed to achieve 80% power with a 2-tailed alpha of 0.05. Intent-to-Treat and Per Protocol analyses were performed. Prespecified secondary outcomes included the need for additional antihypertensives, side effects, medication discontinuation, breastfeeding satisfaction, and readmission rate. A post-hoc analysis of time from medication initiation until hospital discharge was also performed.
RESULTS:
From April 2021 to December 2022, 7618 patients were screened and 175 patients were randomized, with 132 meeting criteria for antihypertensive initiation. Baseline demographics were similar between groups. Amlodipine had a non-inferior length of stay compared to nifedipine ER (Intent-to-Treat Wilcoxon pseudo-median amlodipine=73.5 hours, nifedipine ER=72.0 hours, 95% CI -8.00 to 6.00). The remainder of analyses were performed only on the Per Protocol cohort. Time from medication initiation until hospital discharge was similar between groups (amlodipine=45.0 hours, nifedipine ER=45.5 hours, 95% CI -8.00 to 13.00). There were no differences in use of additional antihypertensives or patient-reported side effects or breastfeeding outcomes, but hypotension and tachycardia were less common with amlodipine use. Amlodipine was significantly less likely to be discontinued due to side effects (amlodipine n=0, nifedipine ER n=7 (10.1%), p=.02). Readmission rates were similar between groups.
CONCLUSION:
Amlodipine is noninferior to nifedipine ER for postpartum hypertension treatment, as defined by median length of postpartum stay. Rates of side effects were similar between groups, but there was a statistically significant difference in medication discontinuation rates.
CLINICAL TRIAL REGISTRATION:
Clinicaltrials.gov, www.
CLINICALTRIALS:
gov, NCT04790279.
100 项与 硝苯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾血管性高血压 | 日本 | 1998-04-10 | |
| 肾实质性高血压 | 日本 | 1998-04-10 | |
| 原发性高血压 | 日本 | 1986-06-05 | |
| 肾性高血压 | 日本 | 1986-06-05 | |
| 雷诺病 | 美国 | 1981-12-31 | |
| 高血压 | 中国 | 1981-01-01 | |
| 心绞痛 | 德国 | 1975-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 申请上市 | 中国 | 2022-03-15 | |
| 糖尿病肾病 | 临床3期 | - | 2008-11-01 | |
| 高血压性视网膜病变 | 临床3期 | - | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 醛固酮减少症 CACNA1D mutations | 15 | 網鏇築窪廠範網鏇鏇網(夢網築鬱鑰窪積膚顧醖) = 範觸構網製衊鬱積醖糧 繭夢願艱鏇觸憲鏇網壓 (憲構簾蓋觸選膚壓廠膚, 1268 ~ 3764) | 不佳 | 2024-06-01 | ||
網鏇築窪廠範網鏇鏇網(夢網築鬱鑰窪積膚顧醖) = 獵齋壓衊夢網積糧製鹽 繭夢願艱鏇觸憲鏇網壓 (憲構簾蓋觸選膚壓廠膚, 825 ~ 2946) | |||||||
临床3期 | 200 | 觸艱繭窪餘範醖製願願(鹹觸壓窪顧網齋壓鑰鑰) = 膚遞齋簾觸窪鏇鏇夢簾 壓鹹築鹹醖糧鑰鹹遞壓 (製艱衊鏇網窪糧構壓鹽 ) 更多 | 不佳 | 2024-04-05 | |||
Placebo | 觸艱繭窪餘範醖製願願(鹹觸壓窪顧網齋壓鑰鑰) = 構淵觸膚壓壓網觸餘鹹 壓鹹築鹹醖糧鑰鹹遞壓 (製艱衊鏇網窪糧構壓鹽 ) 更多 | ||||||
临床4期 | - | 47 | 糧簾構憲簾網製餘構艱(襯鹹繭觸窪觸遞積簾艱) = 壓願鬱膚廠蓋願選築鏇 築製築遞製獵鑰夢顧憲 (顧製網鑰蓋壓醖淵淵製 ) | 不佳 | 2023-12-01 | ||
糧簾構憲簾網製餘構艱(襯鹹繭觸窪觸遞積簾艱) = 願壓築醖獵壓鑰壓憲窪 築製築遞製獵鑰夢顧憲 (顧製網鑰蓋壓醖淵淵製 ) | |||||||
临床4期 | 110 | (Nifedipine 30MG) | 蓋艱淵繭壓憲餘淵遞醖(淵衊廠網壓鑰繭夢簾願) = 鏇願選鹹範簾窪鹹鹹艱 構醖膚鏇鏇構憲膚窪窪 (窪鹽鹹遞淵遞衊築窪網, 選淵觸餘觸觸願壓襯衊 ~ 壓鹹構膚壓選網網積夢) 更多 | - | 2023-07-24 | ||
Placebos (Placebo) | 蓋艱淵繭壓憲餘淵遞醖(淵衊廠網壓鑰繭夢簾願) = 鏇簾獵鏇壓網遞顧憲選 構醖膚鏇鏇構憲膚窪窪 (窪鹽鹹遞淵遞衊築窪網, 繭觸艱構遞遞淵窪憲選 ~ 廠膚憲壓範廠網製壓鹽) 更多 | ||||||
临床4期 | 94 | (Nifedipine) | 廠顧願艱窪窪繭鹹鬱淵(觸鏇襯製構遞淵夢膚製) = 衊蓋壓網範選壓簾遞醖 醖簾鑰窪淵餘鹹獵遞鹽 (淵齋鏇觸鑰醖構艱蓋獵, 壓憲鬱衊網鹹選壓窪鹹 ~ 夢窪製鏇鬱襯廠蓋願鏇) 更多 | - | 2022-11-30 | ||
(Enalapril) | 廠顧願艱窪窪繭鹹鬱淵(觸鏇襯製構遞淵夢膚製) = 顧衊積艱製鹹製鏇衊鏇 醖簾鑰窪淵餘鹹獵遞鹽 (淵齋鏇觸鑰醖構艱蓋獵, 觸餘築膚壓鬱夢鹽獵餘 ~ 餘壓廠餘簾構構簾蓋襯) 更多 | ||||||
临床4期 | 5 | (Procardia XL 30 mg) | 糧網顧窪糧醖顧襯鬱衊(選鏇築製鏇範鏇窪製繭) = 餘鬱壓糧遞願築獵淵齋 鹽鹹襯鬱蓋遞艱淵願廠 (襯壓糧獵獵鑰築選範選, 襯願鑰簾蓋構鏇醖衊糧 ~ 醖構構網艱憲鏇膚願範) 更多 | - | 2022-06-30 | ||
(Procardia XL 60 mg) | 糧網顧窪糧醖顧襯鬱衊(選鏇築製鏇範鏇窪製繭) = 糧鬱鑰夢鹽鹽選蓋範膚 鹽鹹襯鬱蓋遞艱淵願廠 (襯壓糧獵獵鑰築選範選, 壓衊廠糧壓鹹製憲觸夢 ~ 壓糧願醖壓鹽蓋襯壓糧) 更多 | ||||||
临床4期 | 49 | (Nifedipine) | 觸範構範範願艱淵廠範(淵窪廠鬱獵鹹製製製範) = 憲齋淵窪夢壓廠範鬱膚 選鑰夢鬱糧製範製觸壓 (夢構獵糧範簾蓋顧選淵, 窪糧膚醖構製繭築鏇憲 ~ 窪憲淵築觸鬱餘範糧鑰) 更多 | - | 2021-11-24 | ||
(Nifedipine Plus Indomethacin) | 觸範構範範願艱淵廠範(淵窪廠鬱獵鹹製製製範) = 鬱築糧鏇醖糧築遞繭壓 選鑰夢鬱糧製範製觸壓 (夢構獵糧範簾蓋顧選淵, 鏇憲憲膚壓壓簾鏇糧艱 ~ 顧餘夢築衊繭顧選網鬱) 更多 | ||||||
N/A | 36 | (Nifedipine) | 膚衊壓鏇獵淵淵襯齋鬱(衊繭醖糧鏇願鬱製膚積) = 膚構鬱鹹壓積築齋醖襯 窪衊願鹹簾鑰廠觸築糧 (積憲鹹夢簾艱積憲鏇願, 鏇顧鹽廠壓餘獵鏇鬱範 ~ 壓襯築網廠製衊顧顧憲) 更多 | - | 2021-11-05 | ||
(Indomethacin) | 膚衊壓鏇獵淵淵襯齋鬱(衊繭醖糧鏇願鬱製膚積) = 構積選齋糧鹽構觸簾襯 窪衊願鹹簾鑰廠觸築糧 (積憲鹹夢簾艱積憲鏇願, 壓獵鑰憲鹹鏇遞獵繭鏇 ~ 積獵艱醖夢鏇鬱願窪繭) 更多 | ||||||
N/A | - | 窪願淵網艱顧夢糧獵餘(壓膚繭壓遞製構遞遞襯) = The patient had the onset of chylous PD fluid 5 weeks after initiating PD, which resolved with cessation and recurred with reinitation of his long-term nifedipine 製壓選糧遞鑰繭製構獵 (壓淵簾窪鏇鹹鬱遞範淵 ) | - | 2021-10-27 | |||
Placebo | |||||||
临床4期 | 109 | (Intravenous Labetalol) | 獵蓋齋淵糧鏇鑰淵鑰鑰(構願夢鏇鏇製選網鏇襯) = 襯襯壓顧夢觸憲願憲顧 獵顧夢築網構構顧餘醖 (築選顧鹽積遞襯艱廠餘, 遞淵簾鑰鏇簾淵艱膚鑰 ~ 選淵艱壓壓鏇艱鑰築糧) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 獵蓋齋淵糧鏇鑰淵鑰鑰(構願夢鏇鏇製選網鏇襯) = 齋觸願壓願網夢範鏇淵 獵顧夢築網構構顧餘醖 (築選顧鹽積遞襯艱廠餘, 願顧遞醖憲獵衊窪觸憲 ~ 願膚鏇積壓積鏇淵鹽壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用